Key facts
- This page summarizes Chris P. Recknor's Form 4 filing for CytoDyn Inc. (CYDY).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 08 Jun 2022, 16:06.
Chris P. Recknor - 31 Mar 2022 Form 4 Insider Report for CytoDyn Inc. (CYDY)
- Reporting relationship
- Officer
- Issuer ticker
- CYDY
- Reported as of
- 31 Mar 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Jun 2022, 16:06:27 UTC
- Prior SEC filing
- 10 Aug 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Antonio Migliarese, Attorney-In-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Chris P. Recknor filed Form 4 for CytoDyn Inc. (CYDY) on 08 Jun 2022.
Change
- Previous filing in this sequence was filed on 10 Aug 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CYDY
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +12,950
- Change %
- +1.9%
- Price
- $0.000000
- Shares after
- 699,000
- Date
- 31 Mar 2022
- Ownership
- Direct
- Footnotes
- F1
CYDY
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +17,746
- Change %
- +2.5%
- Price
- $0.000000
- Shares after
- 716,746
- Date
- 15 Apr 2022
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Chris P. Recknor is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary.
SEC remarks
Sr. VP Clinical Operations, Dr Chris P. Recknor served in the position of Sr. VP Clinical Operations until 4/19/2022. EX 24 - Power of Attorney